Treating Influenza and SARS-CoV-2 via mRNA-encoded Cas13a
Blanchard, E. L.; Vanover, D.; Bawage, S. S.; Tiwari, P. M.; Rotolo, L.; Beyersdorf, J.; Peck, H. E.; Bruno, N. C.; Hincapie, R.; Finn, M. G.; Michel, F.; Lafontaine, E. R.; Hogan, R. J.; Zurla, C.; Santangelo, P. J.
Show abstract
Here, Cas13a has been used to target and mitigate influenza virus A (IAV) and SARS-CoV-2 using a synthetic mRNA-based platform. CRISPR RNAs (crRNA) against PB1 and highly conserved regions of PB2 were screened in conjunction with mRNA-encoded Cas13a. Screens were designed such that only guides that decreased influenza RNA levels in a Cas13-mediated fashion, were valid. Cas13a mRNA and validated guides, delivered post-infection, simulating treatment, were tested in combination and across multiplicities of infection. Their function was also characterized over time. Similar screens were performed for guides against SARS-CoV-2, yielding multiple guides that significantly impacted cytopathic effect. Last, the approach was utilized in vivo, demonstrating the ability to degrade influenza RNA in a mouse model of infection, using polymer-formulated, nebulizer-based mRNA delivery. Our findings demonstrate the applicability of Cas13a in mitigating respiratory infections both in vitro and in a mouse model, paving the way for future therapeutic use.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by virus-like particle 95%
- CRISPRCas9-mediated gene disruption of endogenous co-receptors confers broad resistance to HIV-1 in human primary cells and humanized mice 94%
- Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate 94%
Similar papers in this journal
- Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance 96%
- Efficient genome replication in influenza A virus requires NS2 and sequence beyond the canonical promoter 96%
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
Similar papers in this journal
- AAVone: A Cost-Effective, Single-Plasmid Solution for Efficient AAV Production with Reduced DNA Impurities 94%
- Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy 93%
- Single intravitreal administration of a tetravalent siRNA exhibits robust and efficient gene silencing in rodent and swine photoreceptors 93%
Similar papers in this journal
- Mechanistic Insights into Dengue Virus Inhibition by a Clinical Trial Compound NITD-688 95%
- Structure-first identification of conserved RNA elements that regulate dengue virus genome architecture and replication. 94%
- 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses 94%
Similar papers in this journal
- Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer 94%
- Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity 94%
- Evolving Membrane-Associated Accessory Protein Variants for Improved Adeno-Associated Virus Production 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.